Table 4.
Factors associated with treatment duration among 2653 HCV-infected individuals eligible for 8 weeks of ledipasvir/sofosbuvir
| 8 weeks | 12 weeks | ||
|---|---|---|---|
| n (row %) | n (row %) | ||
| Overall | 1958 (73.8) | 695 (26.2) | P |
|
| |||
| Race/ethnicity | 0.08 | ||
| White | 1139 (75.4) | 371 (24.6) | |
| Black | 324 (72.0) | 126 (28.0) | |
| Hispanic | 227 (68.6) | 104 (31.4) | |
| Asian | 124 (73.8) | 44 (26.2) | |
| Other | 113 (76.9) | 34 (23.1) | |
|
| |||
| Age in years | <0.001 | ||
| <50 | 330 (84.2) | 62 (15.8) | |
| 50–59 | 686 (75.1) | 227 (24.9) | |
| ≥60 | 942 (69.9) | 406 (30.1) | |
|
| |||
| Sex | <0.001 | ||
| Female | 903 (80.1) | 224 (19.9) | |
| Male | 1055 (69.1) | 471 (30.9) | |
|
| |||
| Transient elastography kPa | <0.001 | ||
| <9.5 | 853 (88.8) | 108 (11.2) | |
| 9.5–11 | 78 (57.8) | 57 (42.2) | |
| 11.1–11.9 | 8 (16.7) | 40 (83.3) | |
|
| |||
| FIB-4 (if no transient elastography) | <0.001 | ||
| <1.45 | 502 (87.3) | 73 (12.7) | |
| 1.45–3.25 | 472 (66.0) | 243 (34.0) | |
| 3.26–5.88 | 45 (20.6) | 174 (79.5) | |
|
| |||
| Creatinine >1.1 mg/dL | 0.10 | ||
| No | 1746 (74.3) | 603 (25.7) | |
| Yes | 199 (69.8) | 86 (30.2) | |
|
| |||
| International normalized ratio >1.1 | <0.001 | ||
| No | 1889 (75.5) | 613 (24.5) | |
| Yes | 44 (36.4) | 77 (63.6) | |
|
| |||
| Bilirubin >1.1 g/dL | <0.001 | ||
| No | 1876 (75.5) | 610 (24.5) | |
| Yes | 77 (48.1) | 83 (51.9) | |
|
| |||
| Albumin <3.6 g/dL | <0.001 | ||
| No | 1852 (75.6) | 599 (24.4) | |
| Yes | 43 (35.3) | 79 (64.8) | |
|
| |||
| Diabetes | <0.001 | ||
| No | 1734 (77.0) | 519 (23.0) | |
| Yes | 224 (56.0) | 176 (44.0) | |
|
| |||
| Body mass index >30 kg/m2 | <0.001 | ||
| No | 1315 (76.1) | 414 (23.9) | |
| Yes | 547 (66.8) | 272 (33.2) | |
|
| |||
| Alcoholic drinks per week | 0.001 | ||
| 0 | 1569 (72.9) | 583 (27.1) | |
| 1–7 | 254 (81.4) | 58 (18.6) | |
| 8–14 | 48 (76.2) | 15 (23.8) | |
| ≥15 | 13 (48.2) | 14 (51.9) | |
|
| |||
| Drug abuse | 0.88 | ||
| No | 1595 (73.7) | 568 (26.3) | |
| Yes | 363 (74.1) | 127 (25.9) | |
|
| |||
| Smoking | 0.30 | ||
| No | 1202 (74.5) | 411 (25.5) | |
| Yes | 756 (72.7) | 284 (27.3) | |
|
| |||
| Hepatitis B virus infection | 0.023 | ||
| No | 1869 (74.3) | 648 (25.7) | |
| Yes | 89 (65.4) | 47 (34.6) | |
HCV, hepatitis C virus. Eligibility for 8 weeks was defined as genotype 1, treatment-naive, no cirrhosis (i.e., transient elastography <12 kPa if available, else FIB-4 ≤5.88), HIV-uninfected, and HCV RNA <6 million IU/mL.